- •
Merkel cell carcinoma (MCC) is a rare, highly aggressive cutaneous neuroendocrine malignancy.
- •
Most MCC tumors are associated with Merkel cell polyomavirus (MCPyV), which expresses viral oncoproteins including large T and small T antigens.
- •
A panel of immunohistochemical markers is necessary for the diagnosis of MCC and distinction from morphologically similar tumors involving the skin.
- •
MCCs do not consistently display activation of cellular oncogenes for which clinical inhibitors are available,
Update on Merkel Cell Carcinoma
Section snippets
Key points
Epidemiology
As of 2011, the annual incidence of MCC in the United States was 0.79 per 100,000, with slightly lower incidence in Europe and higher incidence in Australia.1, 10 There is higher incidence in fair-skinned populations.1 The incidence of MCC has displayed a greater than three-fold increase in the past three decades, accompanied by increased mortality.10
MCC risk is influenced by patient factors including ethnicity, age, sex, and medical history. Greater than 95% of individuals with MCC are white.11
Clinical presentation
MCC classically presents as a rapidly growing, firm, red or violaceous nodule on sun-exposed skin.12 Clinical findings have been described by the AEIOU acronym (asymptomatic/lack of tenderness, expanding rapidly, immune suppression, older than 50 years, ultraviolet-exposed site on fair skin).12 The clinical differential diagnosis often includes cyst, lipoma, or nonmelanoma skin cancer.12, 13
Scanning Magnification Features
A basic approach for histopathologic evaluation of MCC is shown in Box 1. At low power, MCC typically forms a large nodule with infiltrative borders in the dermis or subcutis (Fig. 1A).14 Circumscribed nodules or entirely infiltrative patterns (see Fig. 1B) may also be seen. Areas of cordlike or trabecular growth through thickened collagen are often present (see Fig. 1C). Some tumors display organoid patterning (see Fig. 1D, E). Tumor necrosis is common. Stromal changes may include mucin (see
Clinical course, staging, and prognosis
MCC has a high rate of metastasis and mortality. A total of 26% of cases present with nodal metastatic disease, and 8% with distant metastatic disease.11 In-transit and satellite cutaneous metastases can occur. Distant metastases may involve the skin, liver, bone, brain, or central nervous system. Reported mortality estimates vary. A recent study of 9387 patients reported 5-year overall survival rates of 51% for local disease, 35% for nodal disease, and 14% for distant disease.11
The strongest
Potential prognostic biomarkers
Several potential prognostic biomarkers have been investigated for MCC.1 Immune markers that may be informative include tumor PD-L1 expression and the presence of CD8+ tumor-infiltrating lymphocytes.55, 56 Proangiogenic factor expression (vascular endothelial growth factor) and vascular density (by CD34) may be associated with worse outcome.57, 58 Other possible markers of poor prognosis include p63 and nuclear expression of survivin.32, 59
Studies examining the prognostic significance of MCPyV
Clinical management
A multidisciplinary approach for the management of MCC is recommended. For local disease, wide local excision with 1- to 2-cm margins is a mainstay of therapy. Current guidelines recommend sentinel lymph node biopsy for all clinically node-negative patients.62 Patients with positive sentinel lymph nodes generally receive lymph node dissection or radiotherapy to the nodal basin. Adjuvant or palliative radiotherapy is useful in some cases. Chemotherapy does not produce a durable response, and is
Cell of Origin
MCCs resemble Merkel cells by immunophenotype and ultrastructure.4, 15 However, Merkel cells are postmitotic, and are not concentrated at the sites where most MCCs arise. MCCs express B-cell markers including PAX5 and immunoglobulins,31, 63 and may harbor clonal immunoglobulin rearrangements,63 raising the possibility of a B-cell origin. More recently, epidermal progenitor cells have emerged as promising candidates for the origin of Merkel cells and possibly MCC.64, 65 Consistent with this
Summary
As an aggressive malignancy with viral etiology and lack of targeted therapies, MCC represents an area of pressing clinical need, and a unique opportunity for tumor biology investigations. MCC must be distinguished from morphologically similar tumors including metastatic small cell carcinoma. Surgical management and radiotherapy are mainstays of current treatment of local and regional disease. Chemotherapy is currently the standard of care for stage IV disease, but promising new therapies
References (85)
- et al.
Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs
Eur J Cancer
(2017) - et al.
The etiology and epidemiology of Merkel cell carcinoma
Curr Probl Cancer
(2010) - et al.
Cytokeratin 20-negative Merkel cell carcinoma is infrequently associated with the Merkel cell polyomavirus
Mod Pathol
(2015) - et al.
Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features
J Am Acad Dermatol
(2008) - et al.
The toker tumor: spectrum of morphologic features in primary neuroendocrine carcinomas of the skin (Merkel cell carcinoma)
Ann Diagn Pathol
(2006) - et al.
Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma
Mod Pathol
(2015) - et al.
Next generation sequencing of cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation
Mod Pathol
(2016) - et al.
TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis
Mod Pathol
(2007) - et al.
Polyomavirus-negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection
J Invest Dermatol
(2017) - et al.
Merkel cell carcinoma: histopathologic and prognostic features according to the immunohistochemical expression of Merkel cell polyomavirus large T antigen correlated with viral load
Hum Pathol
(2015)
Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin
Cell Host Microbe
Merkel cell carcinoma with cytokeratin 20-negative and thyroid transcription factor-1-positive immunostaining admixed with squamous cell carcinoma
J Dermatol Sci
Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of stage III patients
Mod Pathol
Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma
J Am Acad Dermatol
Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes
J Am Acad Dermatol
Expression profiles associated with aggressive behavior in Merkel cell carcinoma
Mod Pathol
Nuclear expression of survivin portends a poor prognosis in Merkel cell carcinoma
Mod Pathol
Mammalian Merkel cells are descended from the epidermal lineage
Dev Biol
Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice
J Invest Dermatol
Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7
Cell Host Microbe
Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinoma
Mod Pathol
Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc
J Invest Dermatol
Merkel cell carcinoma dependence on Bcl-2 family members for survival
J Invest Dermatol
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Lancet Oncol
Trabecular carcinoma of the skin
Arch Dermatol
Trabecular carcinoma of the skin: an ultrastructural study
Cancer
Clonal integration of a polyomavirus in human Merkel cell carcinoma
Science
The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma
Cancer Res
UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas
Cancer Res
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
Oncotarget
Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States
Am Surg
Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system
Ann Surg Oncol
Merkel cell polyomavirus expression in Merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas
Am J Surg Pathol
Merkel cell carcinoma: histologic features and prognosis
Cancer
Merkel cell carcinoma: review
Adv Anat Pathol
Merkel cell carcinoma arising within a poroma: report of two cases
J Cutan Pathol
Primary cutaneous neuroendocrine carcinoma within a cystic trichoblastoma: a nonfortuitous association?
Am J Dermatopathol
Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma
Rare Tumors
Cytokeratin and neurofilament protein staining in Merkel cell carcinoma of the small cell type and small cell carcinoma of the lung
Am J Dermatopathol
Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers
Histopathology
Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites
Am J Surg Pathol
Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas
Arch Pathol Lab Med
Cited by (0)
No relevant conflicts of interest to disclose.